Shares of Moderna (NASDAQ: MRNA) climbed 6.5% on Wednesday after the European Commission granted a conditional marketing authorization (CMA) for its COVID-19 vaccine.
The CMA will allow the drug to be given to adults aged 18 and older throughout the European Union. To accelerate the rollout, the European Medicines Agency (EMA) ordered an additional 80 million doses of Moderna's vaccine, bringing its total order to 160 million doses. The first deliveries are scheduled to start next week.
Moderna scored another regulatory victory on Wednesday. Image source: Getty Images.
Source Fool.com